

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

IMMTECH INTERNATIONAL INC

Form S-3/A

October 31, 2003

As filed with the Securities and Exchange
Commission on October 31, 2003

Registration Statement No. 333-108278

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-3/A (Amendment No. 1)

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

IMMTECH INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

39-1523370
(I.R.S. Employer Identification Number)

150 Fairway Drive, Suite 150
Vernon Hills, Illinois 60061
(847) 573-0033
(Address, including zip code, and telephone
number, including area code, of registrant's principal
executive offices)

T. Stephen Thompson, President
150 Fairway Drive, Suite 150
Vernon Hills, Illinois 60061
(847) 573-0033
(Name, address, including zip code, and telephone number,
including area code, of agent for service)

Copy to: John F. Fritts, Esq.
Cadwalader, Wickersham & Taft
100 Maiden Lane
New York, New York 10038-4892

(Approximate date of commencement of proposed sale to the public)
From time to time after the effective date of this Registration Statement.

If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If delivery of the prospectus is expected to be made pursuant to Rule 434,

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

please check the following box. []

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Amount to be registered(1)	Proposed maximum offering price per share(2)	Proposed maximum aggregate offering price(2)
Common Stock, par value \$0.01 per share	3,748,998	\$15.12	\$56,684,84
Common Stock, par value \$0.01 per share	70,000	\$18.83	\$1,318,1

(1) In the event of a stock split, stock dividend or similar transaction involving our common stock, the number of shares registered shall automatically be adjusted to cover the additional shares issuable in such event in accordance with Rule 416(a) under the Securities Act of 1933, as amended ("Securities Act").

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) of the Securities Act. Prices are based on the average of the high and low reported sales prices of the common stock on the American Stock Exchange LLC ("AMEX") on August 21, 2003 and October 27, 2003, respectively. The maximum price per share will be determined from time to time in connection with the issuance by the Registrant or resale by the Selling Stockholders of the shares registered under this Registration Statement.

The registrant amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant files a further amendment, which specifically states that this Registration Statement will thereafter become effective in accordance with Section 8(a) of the Securities Act or until this Registration Statement becomes effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) of the Securities Act, may determine.

The information in this Prospectus is not complete and may be changed. Neither Immtech nor the Selling Stockholders may sell these securities until the Registration Statement filed with the Securities and Exchange Commission (the "SEC") is effective. This Prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to Completion, dated October 31, 2003.

PROSPECTUS

3,818,998 Shares

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

[LOGO] IMMTECH INTERNATIONAL, INC.

Common Stock

This is a public offering of 3,818,998 shares ("Shares") of our Common Stock. We may from time to time offer and sell, subject to American Stock Exchange LLC ("AMEX") rules, up to 1,500,000 Shares for our own account and the stockholders named under the caption "Selling Stockholders" may from time to time offer and sell up to an additional 2,318,998 shares of the Company's Common Stock ("Shares"). The Shares may be sold in transactions occurring either on or off the AMEX at prevailing market prices or at negotiated prices. Sales may be made through brokers or through dealers, who are expected to receive customary commissions or discounts. We will receive no proceeds from the sale of Shares sold by Selling Stockholders under this Prospectus. No period of time has been fixed within which the Shares registered under this Prospectus may be offered or sold. Our obligation to keep the Registration Statement of which this Prospectus is a part effective expires as to 60,000 of the Selling Stockholders' Shares on January 6, 2004, 770,000 Shares on March 20, 2004, 667,144 Shares on June 6, 2004, 41,854 Shares on June 9, 2004, 610,000 Shares on July 16, 2004, 100,000 Shares on July 25, 2004, and 70,000 shares on July 31, 2004 or sooner if all Selling Stockholders' Shares are sold. As used in this Prospectus, the terms "we," "us," "our," the "Company" and "Immtech" mean Immtech International, Inc. and the term "Common Stock" means the common stock of Immtech, \$0.01 par value per share.

Our Common Stock is traded on the AMEX under the symbol "IMM". The last reported sale price of our Common Stock on October 30, 2003 was \$20.99. The address of our principal executive offices is 150 Fairway Drive, Suite 150, Vernon Hills, Illinois 60061, and our telephone numbers are (847) 573-0033 or toll free (877) 898-8038.

INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CONSIDER CAREFULLY THE RISK FACTORS BEGINNING ON PAGE S-1 OF THIS PROSPECTUS BEFORE PURCHASING ANY OF THE COMMON STOCK OFFERED.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS PROSPECTUS, INCORPORATED BY REFERENCE HEREIN OR PROVIDED BY SUPPLEMENT. WE HAVE NOT AUTHORIZED ANYONE ELSE TO PROVIDE YOU WITH DIFFERENT INFORMATION. THIS PROSPECTUS IS NOT AN OFFER TO SELL NOR IS IT SEEKING AN OFFER TO BUY THESE SECURITIES IN ANY JURISDICTION WHERE THE OFFER OR SALE IS NOT PERMITTED. THE INFORMATION CONTAINED IN THIS PROSPECTUS IS CORRECT ONLY AS OF THE DATE OF THIS PROSPECTUS, REGARDLESS OF THE TIME OF THE DELIVERY OF THIS PROSPECTUS OR ANY SALE OF THESE SECURITIES.

TABLE OF CONTENTS

RISK FACTORS.....
ABOUT THIS PROSPECTUS.....
WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION OF DOCUMENTS BY REFERENCE.....
FORWARD-LOOKING STATEMENTS.....
THE COMPANY.....
USE OF PROCEEDS.....
SELLING STOCKHOLDERS.....
DESCRIPTION OF CAPITAL STOCK.....
PLAN OF DISTRIBUTION.....
LEGAL MATTERS.....
EXPERTS.....
INTERESTS OF NAMED EXPERTS AND COUNSEL.....
GLOSSARY.....

-ii-

RISK FACTORS

An investment in the Shares offered by this Prospectus involves a high degree of risk. In addition to the other information contained in this Prospectus, the following risk factors should be considered carefully in evaluating our business before purchasing the Shares.

There is no assurance that we will successfully develop a commercially viable product; our most advanced product candidate is in Phase II human clinical trials.

We are at an early stage of human clinical, and in some cases pre-clinical, development activities required for drug approval and commercialization. Since our formation in October 1984, we have engaged in research and development programs, expanding our network of scientists and scientific advisors, licensing technology agreements and advancing the commercialization of the dication technology platform. We have generated no revenue from product sales and do not have any products currently available for sale, and none are expected to be commercially available for sale until after March 31, 2004, if at all. There can be no assurance that the research we fund and manage will lead to commercially viable products. Our most advanced programs are in the Phase II human clinical testing stage using our lead compound DB289 for several indications including Trypanosomiasis and Malaria and must undergo substantial additional regulatory review prior to commercialization.

We have a history of losses and an accumulated deficit; our future profitability is uncertain.

We have experienced significant operating losses since our inception and we expect to incur additional operating losses as we continue research and development, clinical trial and commercialization efforts. As of June 30, 2003, we had an accumulated deficit of approximately \$44,491,000. Losses from operations were \$4,693,000 and \$1,129,000, respectively, for the fiscal year ended March 31, 2003 and the three-month period ended June 30, 2003.

We will need substantial additional funds in future years to continue our research and development; if financing is not available, we may be required to reduce spending for our research programs, cease operations or pursue other

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

financing alternatives.

Our operations to date have consumed substantial amounts of cash. Negative cash flow from operations is expected to continue in the foreseeable future. Without substantial additional financing, we may be required to reduce some or all of our research programs or cease operations. Our cash requirements may vary materially from those now planned because of results of research and development, results of pre-clinical and clinical testing, responses to our grant requests, relationships with strategic partners, changes in the focus and direction of our research and development programs, competitive and technological advances, the FDA and foreign regulatory process and other factors. In any of these circumstances, we may require substantially more funds than we currently have available or currently intend to raise to continue our business. We may seek to satisfy future funding requirements through public or private offerings of securities, by collaborative or other arrangements with pharmaceutical or biotechnology companies, issuance of debt or from other sources. Additional financing may not be available when needed or may not be available on acceptable terms. If adequate financing is not available,

we may not be able to continue as a going concern or may be required to delay, scale back or eliminate certain research and development programs, relinquish rights to certain technologies or product candidates, forego desired opportunities or license third parties to commercialize our products or technologies that we would otherwise seek to develop internally. To the extent we raise additional capital by issuing equity securities, ownership dilution to existing stockholders will result.

We receive funding primarily from charitable grants, research and development programs and from sales of our equity securities. To date we have directed most of such funds not used for general and administrative overhead toward our research and development and commercialization programs (including preparation of test results for submission to regulatory agencies for product approval). Until one or more of our product candidates is approved for sale, our funding is limited to funds received from testing and research agreements, licensing of our technology and potential fees associated with interim leasing of our properties while we develop them for product manufacture.

Our CEO, T. Stephen Thompson, has been with the Company since April 9, 1991; his relationship with the scientific community and ability to guide the research team may not be easily replaced.

Our CEO, T. Stephen Thompson, has been pivotal in cultivating relationships with our scientists and with the Consortium and should he depart his absence could negatively impact our ability to maintain these important relationships. Further, Mr. Thompson holds a wealth of institutional knowledge which is extremely important in the development of our product candidates, continuing relationships with research institutions and advancement of our business. Mr. Thompson has an employment agreement with us that renews annually unless notice is given at least 30 days prior to the end of each contract year. Mr. Thompson has not indicated that he intends to retire or leave the Company.

Our dependence on key personnel could adversely affect our business if one or more key individuals should depart.

Our business depends to a significant degree on the continuing contributions of our key management, scientific and technical personnel, as well

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

as on the continued discoveries of scientists, researchers and specialists at The University of North Carolina at Chapel Hill ("UNC"), Georgia State University, Duke University and Auburn University (collectively, the "Scientific Consortium") who have entered into a Consortium Agreement, dated January 15, 1997, and a License Agreement, dated as of January 28, 2002, with us by which the Scientific Consortium has given us exclusive world-wide rights to commercialize certain pharmaceutical product candidates that are related to the dication technology developed in the Scientific Consortium members' laboratories.

We rely heavily on in-house and Consortium scientists. From the discovery stage through development and commercialization, Consortium and Immtech scientists are among the foremost authorities in their respective fields. While the body of science may develop without any one particular scientist, our assembled team has a unique blend of talents to advance both the science and the business of medicine. There can be no assurance that the loss of certain members of management or the scientists, researchers and technicians from the Scientific Consortium universities would not materially adversely affect our business.

S-2

Most of the financial aspects of the Company, including investor relations, intellectual property control and corporate governance, are under the direct supervision of two highly talented employees, Cecilia Chan and Gary Parks. Together with Mr. Thompson, Ms. Chan and Mr. Parks hold a wealth of knowledge and business savvy that they utilize to assist the Company to forge new relationships and exploit new business opportunities without diminishing or undermining existing programs and obligations. Neither Ms. Chan nor Mr. Parks have employment contracts with the Company, however, neither has indicated any intention to retire or leave the Company.

We do not have employment contracts with any employees other than our CEO, T. Stephen Thompson.

We have an employment agreement with our CEO, T. Stephen Thompson that renews annually in April of each year unless prior notice is given by either party to the other. Mr. Thompson renewed his employment with the Company this year and has not expressed any indication that he desires to leave the Company or retire. All other Company employees are "at will" employees and may leave at any time, however, none have as of this date, expressed any intention to do so. Much of our proprietary information is developed by scientists who are employed by the universities that comprise the Scientific Consortium. We do not have control over, knowledge of, or access to those employment arrangements. We have not been advised by any of the key members of our Company or of the Scientific Consortium of their intention to leave their employ or the program. We do not have "key-man" life insurance policies on any of our executives, including Mr. Thompson.

Additional research grants needed to fund our operations may not be available or, if available, not on terms acceptable to the Company.

We have funded our product development and operations as of June 30, 2003 through a combination of sales of equity and revenue generated from research agreements funded by grants. As of June 30, 2003, our accumulated deficit is \$44,491,000, of which approximately \$9,327,000 was funded either directly or indirectly with grant funds and payments from research and testing

agreements.

In March 2001 we entered into a clinical research subcontract with UNC, funded by a \$15.1 million grant from The Bill & Melinda Gates Foundation ("The Gates Foundation") to UNC for the study of African sleeping sickness and Leishmaniasis, under which UNC is to pay to us \$9.8 million in installments over a period not to exceed five years based on our achieving certain milestones. We entered into a second subcontract with UNC under which we are to receive over \$2.4 million based on a separate \$2.7 million grant from the Gates Foundation to UNC to accelerate the African sleeping sickness study. We will continue to apply for new grants to support continuing research and development of our dication platform technology and other product candidates. The process of obtaining grants is extremely competitive and there can be no assurance that any of our grant applications will be acted upon favorably. Some charitable organizations may request licenses to our proprietary information or may impose price restrictions on the products we develop with grant funds. We may not be able to negotiate terms that are acceptable to us with such organizations. In the event we are unable to raise sufficient funds to advance our product developments with grant funds we may seek to raise additional capital with the issuance of debt or equity securities. There can be no assurance that we will be able

S-3

to place or sell debt or equity securities on terms acceptable to the Company and, if we sell equity, existing stockholders may suffer dilution (see Risk Factors, this section, entitled "Shares eligible for future sale may adversely affect our ability to sell equity securities," and "Our outstanding options and warrants may adversely affect our ability to consummate future equity financings due to the dilution potential to future investors").

None of our product candidates have been approved for sale by any regulatory agency; approval is required before we can sell drug products commercially.

All of our product candidates, including DB289 and DB075, require additional clinical testing, regulatory approval and development of marketing and distribution channels, all of which are expected to require substantial additional investment prior to commercialization. There can be no assurance that any of our product candidates will be successfully developed, prove to be safe and effective in human clinical trials, meet applicable regulatory standards, be capable of being produced in commercial quantities at acceptable costs, be eligible for third party reimbursement from governmental or private insurers, be successfully marketed or achieve market acceptance. If we are unable to commercialize our product candidates in a timely manner we may be required to seek additional funding, reduce or cancel some or all of our development programs, sell or license some of our proprietary information or cease operations.

There are substantial uncertainties related to clinical trials that may result in the extension, modification or termination of one or more of our programs.

In order to obtain required regulatory approvals for the commercial sale of our product candidates, we must demonstrate through human clinical trials that our product candidates are safe and effective for their intended uses. Prior to conducting human clinical trials we must obtain governmental approvals from the host nation, approval from the U.S. to export our product candidate to the test site and qualify a sufficient number of volunteer patients that meet our trial criteria. If we do not obtain required governmental consents

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

or if we do not enroll a sufficient number of patients in a timely manner or at all, our trial expenses could increase, results may be delayed or the trial may be cancelled.

We may find, at any stage of our research and development, that product candidates that appeared promising in earlier clinical trials do not demonstrate safety or effectiveness in later clinical trials and therefore do not receive regulatory approvals. Despite the positive results of our pre-clinical testing and human clinical trials those results may not be predictive of the results of later clinical trials and large-scale testing. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in various stages of clinical trials, even after promising results had been obtained in early-stage human clinical trials.

Completion of the clinical trials may be delayed by many factors, including slower than anticipated patient enrollment, difficulty in securing sufficient supplies of clinical trial materials or adverse events occurring during clinical trials. For instance, once we obtain permission to run a test, there are strict criteria regulating who we can test. In the case of our Malaria product candidate, we may encounter difficulties in finding potential patients because our initial regimen requires patients to first fail other treatment programs in order to be eligible for our treatment. In a second case, we were forced to cancel a human clinical trial and relocate due to political insurrection in our host nation.

S-4

Completion of testing, studies and trials may take several years, and the length of time varies substantially with the type, complexity, novelty and intended use of the product. Delays or rejections may be based upon many factors, including changes in regulatory policy during the period of product development. No assurance can be given that any of our development programs will be successfully completed, that any Investigational New Drug ("IND") application filed with the FDA (or any foreign equivalent filed with the appropriate foreign authorities) will become effective, that additional clinical trials will be allowed by the FDA or other regulatory authorities, or that clinical trials will commence as planned. There have been delays in our testing and development schedules due to funding and patient enrollment difficulties and there can be no assurance that our future testing and development schedules will be met.

Only one of our product candidates, DB289, has been advanced to human clinical trials.

We currently have only one compound advanced into human clinical trials. This product candidate has shown efficacy for treatment of many indications and is the basis of several of our programs. If the results of future trials of DB289 do not continue to show positive results, or if we determine to reformulate the compound for other reasons, we may need to recommence trials with new formulations at the Phase I safety study stage.

We do not have pharmaceutical manufacturing capability, which could impair our ability to develop commercially viable products at reasonable costs.

Our ability to commercialize product candidates will depend in part upon our ability to have manufactured the product candidates, either directly or through third parties, at a competitive cost and in accordance with FDA and other regulatory requirements. We currently lack facilities and personnel to

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

manufacture our product candidates. There can be no assurance that we will be able to acquire such resources, either directly or through third parties, at reasonable costs, if we develop commercially viable products.

We intend to commence construction of a pharmaceutical manufacturing plant in the People's Republic of China ("PRC") with our subsidiary Immtech Hong Kong Limited. Construction and operation of a pharmaceutical manufacturing facility is subject to various governmental approvals, which may be difficult or impossible to obtain. There can be no guarantee that products manufactured at this facility, if built, will be accepted in the countries where we desire to sell our future products.

We are dependent on third-party relationships for critical aspects of our business; problems that develop in these relationships may increase costs and/or diminish our ability to develop our product candidates.

We use the expertise and resources of strategic partners and third parties in a number of key areas, including (i) research and development, (ii) pre-clinical and human clinical trials and (iii) manufacture of pharmaceutical drugs. We have licensing and exclusive commercialization rights to a dicationic pharmaceutical platform and are developing drugs intended for commercial use based on that platform. This strategy creates risks by placing critical aspects of our business in the hands of third parties, whom we may not be able to control. If these third parties do not

S-5

perform in a timely and satisfactory manner, we may incur costs and delays as we seek alternate sources of such products and services, if available. Such costs and delays may have a material adverse effect on our business if the delays jeopardize our licensing arrangements by causing us to become non-compliant with certain license agreements.

We may seek additional third-party relationships in certain areas, particularly in clinical testing, marketing, manufacturing and other areas where pharmaceutical and biotechnology company collaborators will enable us to develop particular products or geographic markets that are otherwise beyond our current resources and/or capabilities. There is no assurance that we will be able to obtain any such collaboration or any other research and development, manufacturing or clinical trial arrangements. Our inability to obtain and maintain satisfactory relationships with third parties may have a material adverse effect on our business by slowing our ability to develop new products, requiring us to expand our internal capabilities, increasing our overhead and expenses, hampering future growth opportunities or causing us to delay or terminate effected programs.

We are uncertain about the ability to protect or obtain necessary patents and protect our proprietary information; our ability to develop our product candidates would be compromised without adequate intellectual property protection.

We have spent and continue to spend considerable funds to develop our product candidates and we are relying on the potential to exploit commercially without competition the results of our product development. Much of our intellectual property is licensed to us under various agreements including the Consortium Agreement. It is the primary responsibility of the discoverer to develop his, her or its invention confidentially, insure that the invention is

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

unique, and to obtain patent protection. In most cases, our role is to reimburse patent related costs after we determine to develop any such invention. We therefore rely on the inventors to insure that technology licensed to us is adequately protected. Without adequate protection for our intellectual property we believe our ability to realize profits on our future commercialized product would be diminished. Without protection, competitors might be able to copy our work and compete with our products without having invested in the development.

There can be no assurance that any particular patent will be granted or that issued patents will provide us, directly or through licenses, with the intellectual property protection contemplated. Patents and licenses of patents can be challenged, invalidated or circumvented. It is also possible that competitors will develop similar products simultaneously. Our breach of any license agreement or the failure to obtain a license to any technology or process which may be required to develop or commercialize one or more of our product candidates may have a material adverse effect on our business including the need for additional capital to develop alternate technology, the potential that competitors may gain unfair advantage and lessen our expectation of potential future revenues.

The pharmaceutical and biotechnology fields are characterized by a large number of patent filings, and a substantial number of patents have already been issued to other pharmaceutical and biotechnology companies. Third parties may have filed applications for, or may have been issued, certain patents and may obtain additional patents and proprietary rights related to products or processes competitive with or similar to those that we are attempting to develop and commercialize. We may not be aware of all of the patents potentially adverse to our

S-6

interests that may have been issued to others. No assurance can be given that patents do not exist, have not been filed or could not be filed or issued, which contain claims relating to or competitive with our technology, product candidates or processes. If patents have been or are issued to others containing preclusive or conflicting claims, then we may be required to obtain licenses to one or more of such patents or to develop or obtain alternative technology. There can be no assurance that the licenses or alternative technology that might be required for such alternative processes or products would be available on commercially acceptable terms, or at all.

Because of the substantial length of time and expense associated with bringing new drug products to market through the development and regulatory approval process, the pharmaceutical and biotechnology industries place considerable importance on patent and trade secret protection for new technologies, products and processes. Since patent applications in the United States are confidential until patents are issued and since publication of discoveries in the scientific or patent literature often lag behind actual discoveries, we cannot be certain that we (or our licensors) were the first to make the inventions covered by pending patent applications or that we (or our licensors) were the first to file patent applications for such inventions. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions and, therefore, the breadth of claims allowed in pharmaceutical and biotechnology patents, or their enforceability, cannot be predicted. There can be no assurance that any patents under pending patent applications or any further patent applications will be issued. Furthermore, there can be no assurance that the scope of any patent protection will exclude competitors or provide us competitive advantages, that

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

any of our (or our licensors') patents that have been issued or may be issued will be held valid if subsequently challenged, or that others, including competitors or current or former employers of our employees, advisors and consultants, will not claim rights in, or ownership to, our (or our licensors') patents and other proprietary rights. There can be no assurance that others will not independently develop substantially equivalent proprietary information or otherwise obtain access to our proprietary information, or that others may not be issued patents that may require us to obtain a license for, and pay significant fees or royalties for, such proprietary information.

We rely on technology developed by others and shared with collaborators to develop our product candidates.

We rely on trade secrets, know-how and technological advancement to maintain our competitive position. Although we use confidentiality agreements and employee proprietary information and invention assignment agreements to protect our trade secrets and other unpatented know-how, these agreements may be breached by the other party thereto or may otherwise be of limited effectiveness or enforceability.

We are licensed to commercialize technology from a dication platform developed by a Scientific Consortium, comprised primarily of scientists employed by universities in an academic setting. The academic world is improved by the sharing of information. As a business, however, the sharing of information whether through publication of research, academic lectures or general intellectual discourse among contemporaries is not conducive to protection of proprietary information. Our proprietary information may fall into the possession of unintended parties without our knowledge through customary academic information sharing.

S-7

At times we may enter into confidentiality agreements with other companies, allowing them to test our compounds for potential future licensing, in return for milestone and royalty payments should any discoveries result from the use of our proprietary information. We cannot be assured that such parties will honor these confidentiality agreements subjecting our intellectual property to unintended disclosure.

The pharmaceutical and biotechnology industries have experienced extensive litigation regarding patent and other intellectual property rights. We could incur substantial costs in defending suits that may be brought against us (or our licensors) claiming infringement of the rights of others or in asserting our (or our licensors') patent rights in a suit against another party. We may also be required to participate in interference proceedings declared by the U.S. Patent and Trademark Office or similar foreign agency for the purpose of determining the priority of inventions in connection with our (or our licensors') patent applications.

Adverse determinations in litigation or interference proceedings could require us to seek licenses (which may not be available on commercially reasonable terms) or subject us to significant liabilities to third parties, and could therefore have a material adverse effect on our business by increasing our expenses and having an adverse effect on our business. Even if we prevail in an

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

interference proceeding or a lawsuit, substantial resources, including the time and attention of our officers, would be required.

Confidentiality agreements may not adequately protect our intellectual property.

We require our employees, consultants and third-parties with whom we share proprietary information to execute confidentiality agreements upon the commencement of their relationship with us. The agreements generally provide that trade secrets and all inventions conceived by the individual and all confidential information developed or made known to the individual during the term of the relationship will be our exclusive property and will be kept confidential and not disclosed to third parties except in specified circumstances. There can be no assurance, however, that these agreements will provide meaningful protection for our proprietary information in the event of unauthorized use or disclosure of such information. If our unpatented proprietary information is publicly disclosed before we have been granted patent protection, our competitors could be unjustly enriched and we could lose the ability to profitably develop products from such information.

Our industry has significant competition; our product candidates may become obsolete prior to commercialization due to alternative technologies.

The pharmaceutical and biotechnology fields are characterized by extensive research efforts and rapid technological progress. Competition from other pharmaceutical and biotechnology companies and research and academic institutions is intense and other companies are engaged in research and product development for treatment of the same diseases that we target. New developments in pharmaceutical and biotechnology fields are expected to continue at a rapid pace in both industry and academia. There can be no assurance that research and discoveries by others will not render some or all of our programs or products non-competitive or obsolete.

We are aware of other companies and institutions dedicated to the development of therapeutics similar to those we are developing, including Aventis Pharmaceuticals, Inc.,

S-8

Hoffman-LaRoche Ltd., Sanofi-Synthelabo Inc., Pfizer Inc., and Bayer Corporation. Many of our existing or potential competitors have substantially greater financial and technical resources than we do and therefore may be in a better position to develop, manufacture and market pharmaceutical products. Many of these competitors are also more experienced performing pre-clinical testing and human clinical trials and obtaining regulatory approvals. The current or future existence of competitive products may also adversely affect the marketability of our product candidates.

In the event some or all of our programs are rendered non-competitive or obsolete, we do not currently have alternative strategies to develop new product lines or financial resources to pursue such a course of action.

There is no assurance that we will receive FDA or corollary foreign approval for any of our product candidates for any indication; we are subject to government regulation for the commercialization of our product candidates.

We have not made application to the U.S. FDA or any other regulatory agency to sell commercially or label any of our product candidates. We or our test collaborators have received licenses from the FDA to export DB289 for

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

testing purposes and have been approved to conduct human clinical trials for various indications in each of the Democratic Republic of Congo, Angola, Thailand and Peru.

All new pharmaceutical drugs and biologics, including our product candidates, are subject to extensive and rigorous regulation by the federal government, principally the FDA under the Federal Food, Drug and Cosmetic Act ("FDCA") and other laws including, in the case of biologics, the Public Health Services Act, and by state, local and foreign governments. Such regulations govern, among other things, the development, testing, manufacture, labeling, storage, pre-market clearance or approval, advertising, promotion, sale and distribution of pharmaceutical drugs and biologics. If drug products or biologics are marketed abroad, they are subject to extensive regulation by foreign governments. Failure to comply with applicable regulatory requirements may subject us to administrative or judicially imposed sanctions such as civil penalties, criminal prosecution, injunctions, product seizure or detention, product recalls, total or partial suspension of production and FDA refusal to approve pending applications.

Each of our product candidates must be approved for each indication for which we believe it to be viable. We have not yet determined from which regulatory bodies we will seek approval for our product candidates or for which indications. Once determined, the approval process is subject to those agencies' policies and acceptance of those agencies' approvals, if obtained, in the countries where we intend to market our product candidates.

We have not received regulatory approval in the United States or any foreign jurisdiction for the commercial sale of any of our product candidates.

The process of obtaining FDA and other required regulatory approvals, including foreign approvals, often takes many years and varies substantially based upon the type, complexity and novelty of the products involved and the indications being studied. Furthermore, the approval process is extremely expensive and uncertain. There can be no assurance that our product candidates will be approved for commercial sale in the United States by the FDA or regulatory

S-9

agencies in foreign countries. The regulatory review process can take many years and we will need to raise additional funds to complete the regulatory review process for our current product candidates. Therefore, the failure to receive FDA approval would have a material adverse effect on our business by precluding us from marketing and selling such products in the United States and preventing us from representing to other nations that the U.S. FDA has approved our products to facilitate accelerated review procedures in those nations and therefore negatively impacting our ability to generate future revenues. Even if regulatory approval of a product is granted, there can be no assurance that we will be able to obtain the labeling claims (a labeling claim is a product's description and its FDA permitted uses) necessary or desirable for the promotion of such product. FDA regulations prohibit the marketing or promotion of a drug for unapproved indications. Furthermore, regulatory marketing approval may entail ongoing requirements for post-marketing studies if regulatory approval is

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

obtained; we will then be subject to ongoing FDA obligations and continued regulatory review. In particular, we, or our third party manufacturers, will be required to adhere to Good Manufacturing Practices ("GMP"), which require us (or our third party manufacturers) to manufacture products and maintain records in a prescribed manner with respect to manufacturing, testing and quality control. Further, we (or our third party manufacturers) must pass a manufacturing facilities pre-approval inspection by the FDA or corollary agency before obtaining marketing approval. Failure to comply with applicable regulatory requirements may result in penalties, such as restrictions on a product's marketing or withdrawal of the product from the market. In addition, identification of certain side effects after a drug is on the market or the occurrence of manufacturing problems could cause subsequent withdrawal of approval, reformulation of the drug, additional pre-clinical testing or clinical trials and changes in labeling of the product.

Prior to the submission of an application for FDA approval, our pharmaceutical drugs and biologics undergo rigorous pre-clinical and clinical testing, which may take several years and the expenditure of substantial financial and other resources. Before commencing clinical trials in humans in the United States, we must submit to the FDA and receive clearance of an IND. There can be no assurance that submission of an IND for future clinical testing of any of our product candidates under development or other future product candidates would result in FDA permission to commence clinical trials or that we will be able to obtain the necessary approvals for future clinical testing in any foreign jurisdiction. Further, there can be no assurance that if such testing of product candidates under development is completed, any such drug compounds will be accepted for formal review by the FDA or any foreign regulatory body or approved by the FDA for marketing in the United States or by any such foreign regulatory bodies for marketing in foreign jurisdictions.

If a product is regulated as a biologic, the FDA will require the submission and approval of both a Product License Application ("PLA") and an Establishment License Application ("ELA") before commercial marketing can commence. The PLA must include detailed information about the biologic, its manufacture and the results of product development, pre-clinical studies and clinical trials. The FDA's time to review PLAs and ELAs averages two to five years. The FDA may ultimately decide that the PLA and ELA do not satisfy the regulatory criteria for approval and deny approval or require additional clinical studies. Future federal, state, local or foreign legislation or administrative acts could also prevent or delay regulatory approval of our pharmaceutical drug and biologic candidates. We anticipate filing a

S-10

NDA with the FDA for compassionate use of DB289 as a treatment for Trypanosomiasis in sub-sahara Africa in calendar year 2005.

Our most advanced programs are developing products intended for sale in countries that may not have established pharmaceutical regulatory agencies.

Some of the intended markets for our treatment of African sleeping sickness and Malaria are in countries without developed pharmaceutical regulatory agencies. We plan in such cases to try first to obtain regulatory approval from a recognized body such as the U.S. FDA or one or more European agencies and then to apply to the targeted country for recognition of the foreign approval. There can be no assurance that the governments of our intended markets will accept foreign approvals or will not require additional

documentation or testing.

There is uncertainty regarding the availability of health care reimbursement for purchasers of our anticipated products; health care reform may negatively impact the ability of prospective purchasers of our anticipated products to pay for such products.

Our ability to commercialize any of our product candidates will depend in part on the extent to which reimbursement for the costs of the resulting drug or biologic will be available from government health administration authorities, private health insurers, charities and others. Many of our product candidates, including treatments for Trypanosomiasis, Malaria and Tuberculosis, would be in the greatest demand in developing nations, many of which do not maintain comprehensive health care systems with the financial resources to pay for such drugs. We do not know to what extent governments, private charities, international organizations and others would contribute toward bringing newly developed drugs to developing nations. Even among drugs sold in developed countries, significant uncertainty exists as to the reimbursement status of newly approved health care products. There can be no assurance of the availability of third-party insurance reimbursement coverage enabling us to establish and maintain price levels sufficient for realization of a profit on our investment in developing pharmaceutical drugs and biologics. Government and other third-party payers are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for new drug or biologic products approved for marketing by the FDA and by refusing, in some cases, to provide any coverage for uses of approved products for disease indications for which the FDA has not granted marketing approval. If adequate coverage and reimbursement levels are not provided by government and third-party payers for uses of our anticipated products, the market acceptance of these products would be adversely affected.

Health care reform proposals are continually introduced in Congress and in various state legislatures and there is no guarantee that such proposals will not be introduced in the future. We cannot predict when any proposed reforms will be implemented, if ever, or the effect of any implemented reforms on our business. Implemented reforms may have a material adverse effect on our business by reducing or eliminating the availability of third-party reimbursement for our anticipated products or by limiting price levels at which we are able to sell such products. If reimbursement is not available for our products, health care providers may prescribe alternative remedies if available. Patients, if they cannot afford our products, may do without. In addition, if we are able to commercialize products in overseas markets, then our ability to achieve success in such markets may depend, in part, on the health care financing and

S-11

reimbursement policies of such countries. We cannot predict changes in health care systems in foreign countries, and therefore, do not know the effects on our business of possible changes.

Shares eligible for future sale may adversely affect our ability to sell equity securities.

Sales of our Common Stock (including the issuance of shares upon conversion of preferred stock) in the public market could materially and

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

adversely affect the market price of shares because prior sales have been executed at or below our current market price. We have three outstanding series of outstanding preferred stock that convert to Common Stock at prices equivalent to \$4.42, \$4.00, and \$4.42, respectively, for our Series A, Series B and Series C Convertible Preferred Stock. Our obligation to convert the Preferred Stock upon demand by the holders may depress the price of our Common Stock and also make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that we deem appropriate.

As of October 29, 2003, we had 9,338,463 shares of Common Stock outstanding, plus (1) 97,800 shares of Series A Convertible Preferred Stock, convertible into approximately 553,176 shares of Common Stock at the conversion rate of 1:5.6562, (2) 20,725 shares of Series B Convertible Preferred stock convertible into approximately 129,531 shares of Common Stock at the conversion rate of 1:6.25, (3) 125,352 shares of Series C Convertible Preferred Stock convertible into approximately 708,998 shares of Common Stock at the conversion rate of 1:5.6562, (4) 707,924 options to purchase shares of Common Stock with a weighted-average exercise price of \$4.54 per share and (5) 2,834,812 warrants to purchase shares of Common Stock with a weighted-average exercise price of \$7.11. Of the shares outstanding, 5,872,109 shares of Common Stock are freely tradable without restriction. All of the remaining 3,466,354 shares are restricted from resale, except pursuant to certain exceptions under the Securities Act of 1933, as amended (the "Securities Act").

Our outstanding options and warrants may adversely affect our ability to consummate future equity financings due to the dilution potential to future investors.

We have outstanding options and warrants for the purchase of shares of our Common Stock with exercise prices currently below market which may adversely affect our ability to consummate future equity financings. The holders of such warrants and options may exercise them at a time when we would otherwise be able to obtain additional equity capital on more favorable terms. To the extent any such options and warrants are exercised, the outstanding shares of our Common Stock will be diluted.

As of October 29, we have outstanding vested options to purchase 492,233 shares of Common Stock at a weighted-average exercise price of 4.79 and vested warrants to purchase 2,718,132 shares of Common Stock with a weighted-average price of 6.96. All outstanding options and warrants have exercise prices below \$20.99, the closing sale price of our Common Stock on October 30, 2003.

Due to the number of shares of Common Stock we are obligated to sell pursuant to outstanding options and warrants described above, potential investors may not purchase our

S-12

future equity offerings at market price because of to the potential dilution such investors may suffer as a result of the exercise of the outstanding options and warrants.

The market price of our Common Stock has experienced significant volatility.

The securities markets from time to time experience significant price and volume fluctuations unrelated to the operating performance of particular

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

companies. In addition, the market prices of the common stock of many publicly traded pharmaceutical and biotechnology companies have been and can be expected to be especially volatile. Our common stock price in the 52-week period ended October 29, 2003 had a low of \$1.58 and high of \$22.35. Announcements of technological innovations or new products by us or our competitors, developments or disputes concerning patents or proprietary rights, publicity regarding actual or potential clinical trial results relating to products under development by us or our competitors, regulatory developments in both the United States and foreign countries, delays in our testing and development schedules, public concern as to the safety of pharmaceutical drugs or biologics and economic and other external factors, as well as period-to-period fluctuations in our financial results, may have a significant impact on the market price of our Common Stock. The realization of any of the risks described in these "Risk Factors" may have a significant adverse impact on such market prices.

We routinely pay vendors in stock as consideration for their services; this may result in shareholder dilution, additional costs and difficulty retaining certain vendors.

In order for us to preserve our cash resources, we often pay vendors in shares or options to purchase shares of Immtech Common Stock rather than cash. Payments for services in stock may materially adversely affect our shareholders by diluting the value of outstanding shares of our Common Stock. In addition, in situations where we have agreed to register the shares issued to a vendor, this will generally cause us to incur additional expenses associated with such registration. Paying vendors in shares or options to purchase shares of Immtech Common Stock may also limit our ability to contract with the vendor of our choice should that vendor decline payment in stock.

We do not pay dividends on our Common Stock.

We have never declared or paid dividends on our Common Stock and we do not intend to pay any Common Stock dividends in the foreseeable future. Our Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock earn dividends of 6%, 8% and 8% per annum, respectively, each payable semi-annually on each April 15 and October 15 while outstanding, and which, at our option, may be paid in cash or in shares of our Common Stock. On April 15, 2002, October 15, 2002, April 15, 2003 and October 15, 2003, we paid dividends to the holders of our Series A Convertible Preferred Stock in shares of Common Stock and on October 15, 2002, April 15, 2003 and October 15, 2003, we paid dividends to the holders of our Series B Convertible Preferred Stock in shares of Common Stock, and on October 15, 2003 we paid dividends to the holders of our Series C Convertible Preferred Stock in shares of Common Stock, in all cases with fractional shares paid in cash.

S-13

There are limitations on the liability of our directors, and we may have to indemnify our officers and directors in certain instances.

Our Certificate of Incorporation limits, to the maximum extent permitted under Delaware law, the personal liability of our directors for monetary damages for breach of their fiduciary duties as directors. Our Bylaws provide that we will indemnify our officers and directors and may indemnify our employees and other agents to the fullest extent permitted by law. We have entered into indemnification agreements with our officers and directors

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

containing provisions that are in some respects broader than the specific indemnification provisions under Delaware law. The indemnification agreements may require us, among other things, to indemnify such officers and directors against certain liabilities that may arise by reason of their status or service as directors or officers (other than liabilities arising from willful misconduct of a culpable nature), to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified and to obtain directors' and officers' insurance. Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify a director, officer, employee or agent made or threatened to be made a party to an action by reason of the fact that he or she was a director, officer, employee or agent of the corporation or was serving at the request of the corporation, against expenses actually and reasonably incurred in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. Delaware law does not permit a corporation to eliminate a director's duty of care and the provisions of our Certificate of Incorporation have no effect on the availability of equitable remedies, such as injunction or rescission, for a director's breach of the duty of care.

We believe that our limitation of director liability assists us to attract and retain qualified directors. However, in the event a director or the board commits an act that may legally be indemnified under Delaware law, the Company will be responsible to pay for such director(s) legal defense and potentially any damages resulting therefrom. Furthermore, the limitation on director liability may reduce the likelihood of derivative litigation against directors, and may discourage or deter stockholders from instituting litigation against directors for breach of their fiduciary duties, even though such an action, if successful, might benefit the Company and its stockholders. Given the difficult environment and potential for incurring liabilities currently facing directors of publicly-held corporations, we believe that director indemnification is in the best interests of the Company and its stockholders, because it enhances our ability to retain highly qualified directors and reduce a possible deterrent to entrepreneurial decision-making.

Nevertheless, limitations of director liability may be viewed as limiting the rights of stockholders, and the broad scope of the indemnification provisions contained in our Certificate of Incorporation and Bylaws could result in increased expense to the Company. The Board of Directors believes, however, that these provisions will provide a better balancing of the legal obligations of, and protections for, directors and will contribute positively to the quality and stability of our corporate governance. The Board of Directors has concluded that the benefit to stockholders of improved corporate governance outweighs any possible adverse effects on stockholders of reducing the exposure of directors to liability and broadened indemnification rights.

S-14

Product liability exposure may expose us to significant liability.

We do not have pharmaceutical products for sale and we therefore do not carry product liability insurance. However, if we do commercialize drug products we will face risk of exposure to product liability and other claims and lawsuits in the event that the development or use of our technology or prospective products is alleged to have resulted in adverse effects. We may not be able to

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

avoid significant liability exposure. We may not have sufficient insurance coverage and we may not be able to obtain sufficient coverage at a reasonable cost. An inability to obtain product liability insurance at acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our products. A product liability claim could hurt our financial performance. Even if we avoid liability exposure, significant costs could be incurred, potentially damaging our financial performance. We do carry commercial general liability insurance and clinical trials insurance which covers our human clinical trial activities.

ABOUT THIS PROSPECTUS

This document is called a Prospectus and is part of a registration statement on Form S-3 (the "Registration Statement") that we filed with the SEC. Under this Prospectus, we may from time to time sell any combination of the securities described in this Prospectus in one or more offerings. The Company's offerings may total up to 1,500,000 Shares. In addition, the Selling Stockholders also may from time to time collectively offer up to 2,318,998 Shares of our Common Stock plus any additional shares paid to Selling Stockholders as dividends on the preferred shares that are convertible into the Common Stock registered hereunder.

You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making, nor will we make, an offer to sell the common stock in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is current only as of the date on its cover. Our business, financial condition, results of operations and prospects may have changed since that date. You should read this Prospectus together with the additional information described under the heading "Where You Can Find More Information" below.

WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION OF DOCUMENTS BY REFERENCE

We file annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission (the "SEC"), under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You may read and copy any materials that we file with the SEC at the SEC's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549, at 233 Broadway, 16th Floor, New York, New York 10279 and at Northwest Atrium Center, 5000 West Madison Street, Suite 1400, Chicago, Illinois 60661-2511. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Our reports, proxy statements and other documents filed electronically with the SEC are

S-15

available at the website maintained by the SEC at <http://www.sec.gov>. We also make available free of charge on or through our Internet website, <http://www.immtech-international.com>, our annual, quarterly and current reports, and, if applicable, amendments to those reports, filed or furnished pursuant to Section 13(a) of the Exchange Act, as soon as reasonably practicable after we electronically file such reports with the SEC. Information on our website is not

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

a part of this report.

We have filed with the SEC a registration statement on Form S-3 (the "Registration Statement") under the Securities Act with respect to the Shares. This Prospectus, which constitutes a part of that Registration Statement, does not contain all the information contained in that Registration Statement and its exhibits. For further information with respect to the Company and the Shares, you should consult the Registration Statement and its exhibits. The Registration Statement and any of its amendments, including exhibits filed as a part of the Registration Statement or an amendment to the Registration Statement, are available for inspection and copying through the SEC's public reference rooms listed above.

The SEC allows us to "incorporate by reference" in this Prospectus the information that we file with them, which means we can disclose important information to you by referring you to other documents that contain that information. The information we incorporate by reference is considered to be part of this Prospectus and information we later file with the SEC will automatically update and supersede the information in this Prospectus. The following documents filed by us with the SEC pursuant to Section 13 of the Exchange Act (File No. 000-25669) and any future filings under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act made before the termination of the offering are incorporated by reference herein:

- (i) our Amended Annual Report on Form 10-K/A for the fiscal year ended March 31, 2003 and Form 10-Q for the quarter ended June 30, 2003;
- (ii) the description of our Common Stock contained in our registration statement filed with the SEC via Edgar under Section 12 of the Exchange Act on April 29, 1999, including any amendments or reports filed for the purpose of updating such description;
- (iii) our definitive Proxy Statement pursuant to Section 14(A) of the Exchange Act for our 2002 Annual Meeting of the Shareholders;
- (iv) all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report referenced in (i) above;
- (v) our Form 8-A pursuant to Section 12(b) of the Exchange Act filed with the SEC on August 6, 2003;
- (vi) our Registration Statement on Form SB-2/A filed with the SEC on February 11, 1999;
- (vii) our Certificate of Incorporation, as amended, filed as Exhibit 3.1 to the above referenced Registration Statement on Form SB-2/A.

All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment indicating that all securities offered hereby have been sold or

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

deregistering all securities then remaining unsold are expressly incorporated by reference into this Prospectus and to be a part of this Prospectus from the date of filing of such documents.

Statements made in this Prospectus, or in any documents incorporated by reference in this Prospectus as to the contents of any contract or other document are materially complete. For additional information we refer you to the copy of the contract or other document filed as an exhibit to the Registration Statement of which this Prospectus is a part or as an exhibit to the documents incorporated by reference.

We will provide to you a copy of any document incorporated by reference in this Prospectus and any exhibits specifically incorporated by reference in those documents at no cost. You may request copies by contacting us at the following address or telephone numbers: Corporate Secretary, Immtech International, Inc., 150 Fairway Drive, Suite 150, Vernon Hills, Illinois, 60061, Telephone No.: (847) 573-0033 or toll free (877) 898-8038.

Any statement incorporated or deemed incorporated herein by reference will be deemed to be modified or superseded for the purpose of the Registration Statement and this Prospectus to the extent that a statement contained in this Prospectus or in any subsequently filed document modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of the Registration Statement or this Prospectus.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this Prospectus and in the documents incorporated by reference in this Prospectus constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements frequently, but not always, use the words "intends," "plans," "believes," "anticipates" or "expects" or similar words and may include statements concerning our strategies, goals and plans. Forward-looking statements involve a number of significant risks and uncertainties that could cause our actual results or achievements or other events to differ materially from those reflected in such forward-looking statements. Such factors include, among others described in the Prospectus, the following: (i) we are in an early stage of product development, (ii) our technology is in the research and development stage and therefore its potential benefits for human therapy are unproven, (iii) the possibility that favorable relationships with collaborators cannot be established or, if established, will be abandoned by the collaborators before completion of product development, (iv) the possibility that we or our collaborators will not successfully develop any marketable products, (v) the possibility that advances by competitors will cause our product candidates not to be viable, (vi) uncertainties as to the requirement that a drug product may not be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our drug product candidates, (vii) risks relating to requirements for approvals by governmental agencies, such as the Food and Drug Administration, before products can be marketed and the possibility that such approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to market our product candidates successfully, (viii) the risk that our patents could be invalidated or narrowed in scope by judicial

actions or that our technology could infringe upon the patent or other intellectual property rights of third parties, (ix) the possibility that we will not be able to raise adequate capital to fund our operations through the process of commercializing a successful product or that future financing will be completed on unfavorable terms, (x) the possibility that any products successfully developed by us will not achieve market acceptance and (xi) other risks and uncertainties that may not be described herein. We undertake no obligation except as required by securities law to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise in this Prospectus.

THE COMPANY

AN INVESTMENT IN THE SECURITIES OFFERED BY THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. PROSPECTIVE INVESTORS SHOULD CONSIDER CAREFULLY THE INFORMATION PROVIDED UNDER "RISK FACTORS" BEGINNING ON PAGE S-1. A GLOSSARY WHICH DEFINES VARIOUS TERMS USED IN THIS PROSPECTUS BEGINS ON PAGE S-26.

We are a pharmaceutical company focused on the development and commercialization of oral drugs to treat infectious diseases. The Company has development programs that include fungal infections, Malaria, Tuberculosis, Hepatitis C, Pneumocystis carinii pneumonia ("PCP") and tropical medicine diseases, including African sleeping sickness (a parasitic disease also known as Trypanosomiasis) and Leishmaniasis (a parasitic disease that destroys the liver). We hold worldwide patents, patent applications, licenses and rights to license worldwide patents, patent applications and technologies from a scientific consortium and exclusive rights to commercialize products from those patents and licenses that are integral to our business.

Since our formation in October 1984, we have engaged in research and development programs, expanding our network of scientists and scientific advisors, licensing technology agreements and advancing the commercialization of the dication technology platform. We use the expertise and resources of strategic partners and third parties in a number of areas, including (i) research and development, (ii) pre-clinical and human clinical trials and (iii) manufacture of pharmaceutical drugs. We have licensing and exclusive commercialization rights to a dicationic pharmaceutical platform and are developing drugs intended for commercial use based on that platform. Dication pharmaceutical drugs work by blocking life-sustaining enzymes from binding to key sites in the "minor groove" of an organism's deoxyribonucleic acid ("DNA"), killing the infectious organisms that cause fungal, parasitic, bacterial and viral diseases. The key site on an organism's DNA is an area where enzymes interact with the infectious organism's DNA as part of their normal life cycle. Structurally, dications are chemical molecules that have two positively charged ends held together by a chemical linker. The composition of the dications, with positive charges on both ends (shaped like molecular barbells), allows dications to bind (similar to a band-aid) to the negatively charged key sites of an infectious organism's DNA. The bound dications block life sustaining enzymes from attaching to the DNA's key sites, thereby killing the infectious organism.

The dication technology is the result of a research program developed by scientists at UNC, Georgia State University, Duke University and Auburn University (collectively, the "Scientific Consortium"). We entered into an agreement with the Scientific Consortium, dated

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

January 15, 1997, as amended, and a License Agreement, dated as of January 28, 2002 (collectively, the "Consortium Agreement"), to commercialize product candidates resulting from the Scientific Consortium's research, including the dication technology.

USE OF PROCEEDS

We intend to use the proceeds of the sale of Shares under this Prospectus by the Company for general corporate purposes, including for research and development and commercialization efforts. We will not receive any of the proceeds from the sale of the Shares offered by the Selling Stockholders under this Prospectus.

SELLING STOCKHOLDERS

The Selling Stockholders other than Gabriele Group LLC ("Gabriele"), Pacific Dragons Group Limited ("Pacific"), Champion Traders Investments Limited ("Champion"), Wyndham Associates Ltd. ("Wyndham"), Gladden Consultants Ltd. ("Gladden"), Fulcrum Holdings of Australia, Inc. ("Fulcrum"), China Harvest Limited ("China Harvest") and Mr. David Tat-Koon Shu ("Mr. Shu") listed below acquired our Series C Stock in private placements between June 6-9, 2003. Such Selling Stockholders have the right to acquire Shares (i) upon conversion of the Series C Stock or (ii) upon issuance of Common Stock as stock dividends to holders of Series C Stock, granted to them in connection with their participation in the private placements.

Between June 6-9, 2003, the Selling Stockholders purchased in the aggregate 125,352 shares of our Series C Stock for gross proceeds to us of \$3,133,800. We completed our offering of Series C Stock as of June 9, 2003. Subject to adjustment for dilution protection, each share of Series C Stock is convertible into 5.6562 shares of Common Stock, 708,998 shares in the aggregate. The Series C Stock earns an 8% per annum dividend payable semi-annually each April 15th and October 15th, in cash or Common Stock at the Company's option for so long as any Series C Stock remains outstanding. If Common Stock is to be used to pay the Series C Stock dividend, such Common Stock is to be valued at the 10-day volume-weighted average closing-bid price immediately prior to the date of payment. We agreed to use reasonable efforts to register the resale by the Selling Stockholders of the Shares of Common Stock issuable upon conversion of the Series C Stock within 180 days after the date of purchase of the Series C Stock, and to keep such registration effective for the lesser of one year or until all of such Shares are sold.

On July 31, 2002 we entered into an agreement with Gabriele to provide to us management consulting services in connection with our Series B private placement offering. We issued to Gabriele 40,000 shares of our Common Stock and three warrants, each to purchase 10,000 shares of our Common Stock exercisable at \$6.00 per share; the warrants vest when the market price of our Common Stock meets or exceeds \$10, \$15 and \$20 for a period of 20 consecutive trading days, respectively, or if the valuation of our Common Stock in a merger or acquisition meets or exceeds \$10, \$15 and \$20 per share, respectively.

In connection with the formation of Immtech Hong Kong Limited on January 13, 2003, we issued 30,000 shares of Common Stock to each of Pacific and Champion for

their assistance with the agreement. We have agreed to register the resale by Pacific and Champion of the Common Stock and to keep the registration effective for the lesser of one year or until all of such shares of Common Stock are sold.

On March 21, 2003, we entered into an agreement with Wyndham for assistance to be provided to identify potential strategic partners and to assist us to raise up to \$20 million in equity financing. For its services, Wyndham's compensation included 220,000 shares of our Common Stock.

On March 21, 2003, we entered into media production agreements with "winmaxmedia," an operating division of Winmax Trading Group, Inc., to produce digital and video media materials to be used in connection with our fundraising efforts. In connection with the services rendered we issued 100,000 shares of our Common Stock to Gladden, one of the vendors providing services under the media production agreement.

On March 21, 2003 we entered into an agreement with Fulcrum to provide to us services and products including website design, multimedia content, custom customer relations software and increased media and investor exposure. In connection with the services rendered we issued to Fulcrum (i) 100,000 shares of our common stock, (ii) a warrant to purchase 100,000 shares of our Common Stock exercisable at \$6.00 per share, to vest ratably over 12 months and to expire at the latest in two years, (iii) a warrant to purchase 125,000 shares of Common Stock exercisable at \$10.00 per share with all other terms the same as (ii) above and (iv) a warrant to purchase 125,000 shares of our Common Stock exercisable at \$15.00 per share with all other terms the same as (ii) above.

On July 16, 2003, we entered into a consulting arrangement with China Harvest for services to be provided to assist the Company and its subsidiaries to obtain regulatory approval to conduct human clinical trials of the Company's product candidates in the People's Republic of China. For its services, China Harvest was granted a warrant to purchase 600,000 shares of our Common Stock exercisable at \$6.08, with a five year exercise period.

On July 16, 2003, we entered into a Consulting Agreement with Mr. Shu for services to be provided to assist the Company in the formation of a subsidiary and to gain regulatory approvals to enter into human clinical trials of our lead compound, DB289, for treatment of various diseases in the People's Republic of China. For his services, Mr. Shu was granted 10,000 shares of our Common Stock.

On July 25, 2003, we entered into a second consulting arrangement with Fulcrum for services to be provided to assist the Company to list its Common Stock on a recognized securities exchange. For its services, Fulcrum was granted 100,000 shares of Common Stock upon such listing.

The following table sets forth for each Selling Stockholder the number of Shares being registered by this Prospectus. No Selling Stockholder has been an officer, director or employee of Immtech for the past three years. Because the Selling Stockholders may offer all, some or none of their Shares, we cannot provide a definitive estimate of the number of Shares they will hold after such registration. This Prospectus is filed at our expense.

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

Name	Series C Stock	Warrants	Underlying Shares of Common Stock	Shares Beneficially Owned	Shares Registered	Pe CL
China Harvest Limited	0	600,000	600,000	600,000	600,000	
Fulcrum Holdings of Australia Limited	0	350,000	550,000	562,100	550,000	
Wyndham Associates Ltd.	0		220,000	220,000	220,000	
Gladden Consultants Ltd	0		100,000	100,000	100,000	
Gabriele Group LLC	0	30,000	70,000	70,000	70,000	
Vivienne Lee	9,200		52,036	143,603	52,036	
Ma Fa On	6,400		36,199	36,450	36,199	
Tao Wai Ling	5,800		32,805	33,032	32,805	
Cheung Ming Tak	5,800		32,805	46,032	32,805	
Pacific Dragons Group Limited	0		30,000	330,000	30,000	
Champion Traders Investments Limited	0		30,000	30,000	30,000	
Cheung Shuk Kwan	4,800		27,149	27,337	27,149	
Monet Capital Fund I, LP	4,800		27,149	62,337	27,149	
Tsang Wai Ping Alfred	4,400		24,887	37,592	24,887	
Sanford Goldfarb	4,000		22,624	24,781	22,624	
Lau Chu	4,000		22,624	42,085	22,624	
Cheung Yuk Chor Dickie	4,000		22,624	48,669	22,624	
Donald H. Wong	3,400		19,231	46,842	19,231	
Chan Chee Wing	3,200		18,100	19,915	18,100	
Tefa Capital, Inc.	3,200		18,100	18,225	18,100	
Liu Yuk Tong and Wong Gum Wing Caroline	3,000		16,968	35,229	16,968	
Val Busler	2,800		15,837	15,947	15,837	
Li Lo Kwong	2,600		14,706	25,694	14,706	
Jerry Sorkin	2,600		14,706	17,808	14,706	
Lau Kin Yip	2,400		13,575	13,669	13,575	
Ho Siu Man	2,120		11,991	12,074	11,991	
Lau Mei Yin Amy	2,080		11,765	11,846	11,765	
Shum Kit Ching	2,080		11,765	11,846	11,765	
Fukoku Asset Management Ltd	2,000		11,312	51,541	11,312	
John R. Harrington and John R. Harrington, Jr. Trust	3,800		21,493	104,980	21,493	
Hui Chin Ki	2,000		11,312	11,460	11,312	
Mao Frank Tsao Yu	2,000		11,312	11,390	11,312	
Richard M. Schaeffer	2,000		11,312	11,390	11,312	

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

Name	Series C Stock	Warrants	Underlying Shares of Common Stock	Shares Beneficially Owned	Shares Registered	Pe CL
Wingpearl Investments Ltd.	2,000		11,312	39,768	11,312	
Mak Wah	1,920		10,860	10,935	10,860	
John J. Orlando	1,800		10,181	28,402	10,181	
Target Profits Securities Limited	1,768		10,000	10,069	10,000	
Chan Yu Ching	1,768		10,000	10,069	10,000	
Wong Hon Fai Jones	1,768		10,000	16,220	10,000	
John Neal	1,768		10,000	10,069	10,000	
David Tat-Koon Shu	0		10,000	10,000	10,000	
Lee Hon Kit Raymond	1,600		9,050	12,647	9,050	
Ho Cho Chuen	1,600		9,050	9,112	9,050	
Li Wai Yin	1,600		9,050	9,112	9,050	
Thomas J. Krupp II	1,200		6,787	6,834	6,787	
Raymond Carbone	1,000		5,656	5,695	5,656	
Richard H. Harrington	1,000		5,656	15,695	5,656	
Scott Hess	1,000		5,656	10,728	5,656	
John Ketcham	1,000		5,656	5,695	5,656	
Michael Strada	1,000		5,656	5,695	5,656	
Chan Pui Ling Juliana	800		4,525	4,556	4,525	
Dwight B. Crane	800		4,525	18,229	4,525	
James M. Florsheim Trust Account #1	800		4,525	11,902	4,525	
Sum Lan Hing	480		2,715	2,733	2,715	
John J. Coonan	400		2,262	8,735	2,262	
Yeung Lai	400		2,262	2,277	2,262	
Stephen Carter	400		2,262	2,277	2,262	
Ho Mei Yee	400		2,262	2,277	2,262	
Lam Yuk Ying	400		2,262	2,277	2,262	
Michael Dundas	400		2,262	2,277	2,262	
Lau Wai Wah Richard	400		2,262	2,277	2,262	
Lo Mo On	400		2,262	2,277	2,262	
Salvatore Picciallo	400		2,262	2,277	2,262	
Michael Volpe	400		2,262	5,735	2,262	
Martin Boyle	200		1,131	8,057	1,131	
Totals	125,352	980,000	2,318,998	3,128,782	2,318,998	

(1) The corresponding percentages are the quotient of (x) the number of shares beneficially owned and (y) the sum of the 9,338,463 shares of Common Stock outstanding, the number shares of Common Stock issuable upon conversion of Series A Stock, Series B Stock and Series C Stock and such holder's options and warrants exercisable within 60 days of the date of October 31, 2003.

* Less than 1.00%.

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

General

The following are the material terms of our Common Stock. You should refer to the applicable provisions of Delaware law, our Certificate of Incorporation as amended and our Bylaws for additional information. See "Where You Can Find More Information."

Under our Certificate of Incorporation, as amended, our authorized capital stock consists of:

30,000,000 shares of Common Stock; and

5,000,000 shares of Preferred Stock, par value \$0.01 per share.

As of October 29, 2003, we had 9,338,463 shares of Common Stock outstanding (not including 553,176 shares of Common Stock reserved for conversion of Series A Stock, 129,531 Shares of Common Stock reserved for conversion of Series B Stock, 708,998 Shares of Common Stock reserved for conversion of Series C Stock, 707,924 shares of Common Stock reserved for exercise of outstanding options and 2,834,812 shares of Common Stock reserved for exercise of outstanding warrants held by certain investors). Of the shares of Common Stock outstanding, 5,872,109 shares of Common Stock are freely tradable without restriction. All of the remaining 3,466,354 shares are restricted from resale except pursuant to certain exceptions under the Securities Act. All of the Common Stock underlying the outstanding Series C Stock is registered by this Prospectus.

Common Stock

Our Common Stock is traded on the American Stock Exchange LLC ("AMEX") under the symbol "IMM." Each share of our Common Stock entitles the holder to one vote on all matters on which holders are permitted to vote. There is no cumulative voting for election of directors. Accordingly, the holders of a majority of the shares voted can elect all of the nominees for director.

Subject to preferences that may be applicable to any outstanding series of preferred stock, the holders of our Common Stock are entitled to dividends when, and if, declared by the Board of Directors out of funds legally available for that purpose. Upon liquidation, dissolution or winding up, subject to preferences that may be applicable to any outstanding series of Preferred Stock, the holders of our Common Stock are entitled to a pro rata share in any distribution to stockholders. Our Common Stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our Common Stock. All outstanding shares of our Common Stock are fully paid and non-assessable.

PLAN OF DISTRIBUTION

The distribution of the Shares described in this Prospectus may be effected from time to time in one or more transactions either (a) at a fixed price or prices, which may be changed, (b) at market prices prevailing at the time of sale, (c) at prices relating to the prevailing market prices or (d) at negotiated prices. We (subject to Amex rules), and any Selling Stockholders, may offer and sell the

S-23

Shares described in this Prospectus (i) through agents, (ii) through one or more underwriters or dealers, (iii) through a block trade in which the broker or dealer engaged to handle the block trade will attempt to sell the securities as agent, but may position and resell a portion of the block as principal to facilitate the transaction, (iv) directly to one or more purchasers (through a specific bidding or auction process or otherwise), (v) in "at the market offerings," within the meaning of Rule 415(a)(4) of the Securities Act, (vi) through a combination of any of these methods of sale, or (vii) at a fixed exchange ratio in return for other of our securities.

To our knowledge, the Selling Stockholders have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of the Shares, nor is there an underwriter or coordinating broker acting in connection with the proposed sales of Shares by the Selling Stockholders. Any Shares covered by this Prospectus that qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than pursuant to this Prospectus. We will pay all costs and expenses incurred in connection with the registration of the Shares offered by this Prospectus. Any brokerage commissions and similar selling expenses attributable to the sale of Shares by the Selling Stockholders will be borne by the Selling Stockholders.

We have agreed to indemnify the Selling Stockholders and the Selling Stockholders' respective officers, directors, employees and agents, and each person who controls such Selling Stockholders, in certain circumstances against certain liabilities, including liabilities arising under the Securities Act, and the Selling Stockholders have agreed to indemnify us and our directors and officers in certain circumstances against certain liabilities, including liabilities arising under the Securities Act, in each case in connection with this offering.

We or the Selling Stockholders may solicit offers to purchase the Shares directly and we or the Selling Stockholders may sell the Shares directly to institutional or other investors. We or the Selling Stockholders may enter into agreements with agents, underwriters and dealers under which we or the Selling Stockholders may agree to indemnify the agents, underwriters and dealers against certain liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make with respect to these liabilities. Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us or the Selling Stockholders in the ordinary course of business.

If we or any Selling Stockholders offer and sell Shares through an underwriter or underwriters, then we or the Selling Stockholders will execute an underwriting agreement with the underwriter or underwriters. The names of the specific managing underwriter or underwriters, as well as any other underwriters, and the terms of the transactions, including compensation of the underwriters and dealers, which may be in the form of discounts, concessions or commissions, if any, will be described in a prospectus supplement, if applicable, which will be used by the underwriters to make resales of the Shares. If the Selling Stockholders offer and sell the Shares through a dealer, then the Selling Stockholders or an underwriter will sell the Shares to the dealer, as principal. The dealer may then resell the Shares to the public at

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

DB289	The designation given to our lead dication.
Dication	A chemical molecule with two positively charged ends that are held together by a chemical linker. Dications bind to the DNA of infectious organisms.
DNA	A type of molecule made up of polymerized deoxyribonucleotides linked together by phosphate bonds.
ELA	Establishment License Application.
FDA	U.S. Food and Drug Administration.
FDCA	Federal Food, Drug, and Cosmetic Act as Amended.
HCV	Hepatitis C virus, or HCV, is one of the viruses that causes acute and chronic hepatitis. Persons who are chronically infected with Hepatitis C are at an increased risk for the development of cirrhosis and liver cancer.
HIV	HIV is the human immunodeficiency virus most researchers believe causes AIDS.
IND	Investigational New Drug Application, or IND, is a document required to be filed with the FDA prior to performing clinical studies on human subjects in the United States.
Leishmaniasis	An infection caused by a protozoal parasite that affects the skin and abdominal organs, causing ulcers or skin disorders that resemble leprosy.
PCP	Pneumocystis carinii pneumonia ("PCP") is a protozoal infection of the lungs, and most common of the AIDS-associated diseases.
Phase I	Clinical testing in which the safety and pharmacological profile of a new drug is established in humans.
Phase II	Clinical testing in which the effectiveness of a new drug is established in humans. This includes establishing the dose amount and frequency required to achieve a therapeutic effect, the metabolic rate of the administered drug and the toxicity profile in specific patient populations.

PLA	Product License Application.
TB	A disease caused by bacteria, Mycobacterium tuberculosis, that is transmitted by breathing in or eating infected droplets, usually affecting the lungs, although infection of other organ systems can occur.
Trypanosomiasis	An infection caused by a protozoal parasite and transmitted usually by insect bites. Also known as African sleeping sickness.

S-26

=====

TABLE OF CONTENTS

RISK FACTORS.....	S-1
ABOUT THIS PROSPECTUS.....	S-15
WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION OF DOCUMENTS BY REFERENCE.....	S-15
FORWARD-LOOKING STATEMENTS.....	S-17
THE COMPANY.....	S-18
USE OF PROCEEDS.....	S-19
SELLING STOCKHOLDERS.....	S-19
DESCRIPTION OF CAPITAL STOCK.....	S-23
PLAN OF DISTRIBUTION.....	S-23
LEGAL MATTERS.....	S-25
EXPERTS.....	S-25
INTERESTS OF NAMED EXPERTS AND COUNSEL.....	S-25
GLOSSARY.....	S-26

=====

IMMTECH INTERNATIONAL
INC.

3,818,998 Shares
Common Stock

PROSPECTUS

October 31, 2003

Until December 10, 2003, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. this is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

=====

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14. Other Expenses of Issuance and Distribution.

The following table sets forth our estimates of the expenses to be incurred in connection with the offering of the Shares of Common Stock being offered hereby:

SEC registration fee:	\$	4,692.43 (1)
Printing expenses:	\$	3,000.00 (2)
Legal fees and expenses:	\$	35,000.00 (2)
Accounting fees and expenses:	\$	15,000.00 (2)
Miscellaneous expenses:	\$	5,000.00 (2)
TOTAL:	\$	62,692.43 (2)

(1) Includes \$4,585.80, paid on August 27, 2003, and \$106.63, paid on October 31, 2003.

(2) Estimated.

We will pay all costs and expenses incurred in connection with the registration of the Shares. Any brokerage commissions and similar selling expenses attributable to the sale of Shares by the Selling Stockholders will be borne by the Selling Stockholders.

Item 15. Indemnification of Directors and Officers.

Limitation of Director's Liability

Our Certificate of Incorporation, as amended, and Bylaws reduce the liability of directors to the fullest extent permissible under Delaware law. Delaware law permits a corporation to limit the personal liability of a director to the corporation or its shareholders for monetary damages for breach of certain fiduciary duties as a director, provided that the director's liability may not be eliminated or limited for: (a) breaches of the director's duty of loyalty to the corporation or its shareholders; (b) acts or omissions not in good faith or involving intentional misconduct or knowing violations of law; (c) the payment of unlawful dividends or unlawful stock repurchases or redemptions; or (d) transactions in which the director received an improper personal benefit. A director's liability may also not be limited for violation of, or otherwise

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

relieve the corporation or its directors from the necessity of complying with, federal or state securities laws or affect the availability of non-monetary remedies such as injunctive relief or rescission.

Indemnification of Officers and Directors

The provisions of our Bylaws relating to indemnification require that we indemnify our directors and executive officers to the fullest extent permitted under Delaware law, provided that

S-28

we may modify the extent of such indemnification by individual contracts with our directors and executive officers, and provided, further, that we will not be required to indemnify any director or executive officer in connection with a proceeding initiated by such person, with certain exceptions. Delaware law, our Bylaws, and any indemnity agreements may also permit indemnification for liabilities arising under the Securities Act or the Exchange Act.

Item 16. Exhibits and Financial Statement Schedules.

See the Exhibit Index immediately following the Signature Page to this Registration Statement.

Item 17. Undertakings.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the provisions described in Item 15 above, or otherwise, the Company has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

maximum offering price may be reflected in the form of prospectus filed with the Commission under Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

S-29

(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement.

Provided, however, that paragraphs (1)(i) and (1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by us pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered by this Registration Statement, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's Annual Report under Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference into this Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

S-30

SIGNATURES

In accordance with the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, hereunto duly authorized, in the City of Vernon Hills, State of Illinois, on October 31, 2003.

IMMTECH INTERNATIONAL, INC.

By: /s/ T. Stephen Thompson

T. Stephen Thompson
President, Chief Executive Officer and Director

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints T. Stephen Thompson his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and the documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

In accordance with the requirements of the Securities Act of 1933, as amended, this Registration Statement was signed by the following persons in the capacities and on the dates stated.

Signatures	Title
/s/ T. Stephen Thompson ----- T. Stephen Thompson	President, Chief Executive Officer and Director (Principal Executive Officer)
/s/ Gary C. Parks ----- Gary C. Parks	Chief Financial Officer, Treasurer and Secretary (Principal Financial and Accounting Officer)
/s/ Cecilia Chan ----- Cecilia Chan	Executive Vice President and Director
/s/ Harvey R. Colten, M.D. ----- Harvey R. Colten, M.D.	Director
/s/ Judy Lau ----- Judy Lau	Director
/s/ Dr. Levi H.K. Lee ----- Dr. Levi H.K. Lee	Director
/s/ Eric L. Sorkin ----- Eric L. Sorkin	Director
/s/ Frederick W. Wackerle -----	

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

Frederick W. Wackerle

Director

By: /s/ T. Stephen Thompson

T. Stephen Thompson
Attorney-In-Fact

Index to Exhibits

Exhibit -----	Description -----
4.1(1)	Form of Common Stock Certificate
4.2(2)	Certificate of Designation, Series A Convertible Preferred Stock
4.3 (3)	Certificate of Designation, Series B Convertible Preferred Stock
4.4(4)	Certificate of Designation, Series C Convertible Preferred Stock
4.5(4)	Form of Regulation D Subscription Agreement for June 6-9, 2003 Private Place
4.6(4)	Form of Regulation S Subscription Agreement for June 6-9, 2003 Private Place
5.1(5)	Opinion of Cadwalader, Wickersham & Taft
23.1(6)	Consent of Deloitte & Touche LLP dated October 31, 2003
23.2(5)	Consent of Cadwalader, Wickersham & Taft (included in Exhibit 5.1)
24.1(6)	Powers of Attorney (included on Signature Page to this Registration Statement)

- (1) Incorporated by reference to Amendment No. 2 to the Company's Registration Statement on Form SB-2 (Registration Statement No. 333-64393), as filed with the Securities and Exchange Commission on March 30, 1999.
- (2) Incorporated by reference to the Company's Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 14, 2002.
- (3) Incorporated by reference to the Company's Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 25, 2002.
- (4) Incorporated by reference to the Company's Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 10, 2003.
- (5) Incorporated by reference to the Company's Registration Statement on Form S-3 (Registration Statement No. 333-108278) as filed with the Securities

Edgar Filing: IMMTECH INTERNATIONAL INC - Form S-3/A

and Exchange Commission on August 27, 2003.

(6) Filed herewith.